Bim regulates the survival and suppressive capability of CD8(+) FOXP3(+) regulatory T cells during murine GVHD

在小鼠移植物抗宿主病(GVHD)中,Bim 调节 CD8(+)FOXP3(+) 调节性 T 细胞的存活和抑制能力。

阅读:1

Abstract

CD8(+) Foxp3(+) T cells (Tregs) are a potent regulatory population whose functional and ontological similarities to CD4(+) Fox3(+) T cells have not been well delineated. Using an experimental model of graft-versus-host disease (GVHD), we observed that CD8(+) Tregs were significantly less potent than CD4(+) Tregs for the suppression of GVHD. To define the mechanistic basis for this observation, we examined the T-cell repertoire and the transcriptional profile of in vivo-derived CD4(+) and CD8(+) Tregs that emerged early during this disease. Polyclonal and alloantigen-induced CD8(+) Tregs had repertoire diversity that was similar to that of conventional CD8(+) T cells, indicating that a restricted repertoire was not the proximate cause of decreased suppression. Transcriptional profiling revealed that CD8(+) Tregs possessed a canonical Treg transcriptional signature that was similar to that observed in CD4(+) Tregs, yet distinct from conventional CD8(+) T cells. Pathway analysis, however, demonstrated that CD8(+) Tregs had differential gene expression in pathways involved in cell death and survival. This was further confirmed by detailed mRNA sequence analysis and protein expression studies, which demonstrated that CD8(+) Tregs had increased expression of Bim and reduced expression of Mcl-1. Transplantation with CD8(+) Foxp3(+) Bim(-/-) Tregs resulted in prolonged Treg survival and reduced GVHD lethality compared with wild-type CD8(+) Tregs, providing functional confirmation that increased expression of Bim was responsible for reduced in vivo efficacy. Thus, Bim regulates the survival and suppressive capability of CD8(+) Tregs, which may have implications for their use in regulatory T-cell therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。